Back to Agenda
Session 7A: Science, Risk-Based Approaches to Post-Approval Stability Testing
Session Chair(s)
Chi-Wan Chen, PHD
, Pfizer, Inc., United States
This session will examine the need for, and the benefit of, establishing an ICH guideline on science- and risk-based approaches to stability testing for post-approval CMC changes or stability commitment. An outline of a proposal for an ICH guideline on this topic will be described. Predictive tools such as statistical modeling, and Accelerated Stability Assessment Program (ASAP), will be discussed. Utility of prior knowledge to justify reduced stability protocols for legacy products will be presented.
Speaker(s)
Chi-Wan Chen, PHD
, Pfizer, Inc., United States
The Case for a New ICH Guideline on Science- and Risk-Based Approaches to Stability Testing for Post-Approval CMC Changes
Brian Patrick Regler, PHD
Associate Principal Scientist, Merck, United States
Predictive Stability Approaches to Assessing Critical Attributes of Pharmaceutical Products
Anthony Rainosek
, Baxter Healthcare, United States
Leveraging Stability Profiles to Justify a Reduced Stability Program for Legacy Products
Donnie Pulliam, MBA
Manager, Global Regulatory Affairs-CMC, Biogen, United States
Right-Sizing Post-Approval Stability Commitments: A Case-Study and Considerations
Have an account?